SCN9A and tuberculosis: Earlier studies have demonstrated that M. tuberculosis uses two of these BVMOs, EthA and MymA, to activate ETH, highlighting their importance for the pharmacological mechanism of this class of TB drugs (3, –, 5, 20, 21).